What this is
- How it works
- How it works isn't classified yet
- Tested for
- Diabetic Kidney Disease
- Main trialPhase 1
- “The study will be a single center, double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, PK and PD of AP303 following 2-week oral administration to Diabetic Kidney Disease patients.”In the company’s words, NCT06666283 on ClinicalTrials.gov
Other drugs for Diabetic Kidney Disease
- WAL0921Walden Biosciences · Phase 2
- R3R01River 3 Renal Corp. · Phase 2
- IsuzinaxibAptabio Therapeutics, Inc. · Phase 2
- Umbilical Cord Mesenchymal Stem CellsPT. Prodia Stem Cell Indonesia · Phase 1/2
- ALN-ANG3Regeneron · Phase 2
- EvinacumabRegeneron · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 25 Sep 2025 | A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients | |
| Phase 1Completed | 21 Jul 2023 | A Safety, Tolerability, and Pharmacokinetics Study of AP303 in Healthy Subjects | |
| Phase 1Completed | 13 May 2024 | A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in Healthy Chinese Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026